Skip to main navigation

About
Research & Development
Pipeline
Investors
Careers

Press Releases

Press Releases

Year

April 6, 2023

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

March 7, 2023

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

March 2, 2023

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

March 1, 2023

Revolution Medicines Announces Commencement of Public Offering of Common Stock

February 27, 2023

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

February 21, 2023

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

February 2, 2023

Revolution Medicines to Participate in Upcoming Investor Conferences

January 3, 2023

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

December 19, 2022

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

December 7, 2022

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 11 - 20 of 113

Email Alerts

RSS Feeds

Print Page

Contact IR

© 2023 Revolution Medicines, Inc. | 700 Saginaw Drive | Redwood City, CA 94063
CCPA Notice | Privacy Policy

Search Investor Relations